POLRMT: A Drug Target / Disease Biomarker (G5442)

Target Name: POLRMT

NCBI ID: G5442

POLRMT

POLRMT: A Drug Target / Disease Biomarker

POLRMT (PRion-Like RNA Motif) is a protein that is found in the brains of individuals with spongiform encephalopathies (SEs), a group of rare and progressive brain disorders that are characterized by the accumulation of abnormally shaped proteins in the brain. The most well-known of these disorders is Alzheimer's disease, which affects an estimated 50 million people worldwide.

The exact cause of SEs is not known, but it is thought to involve an abnormal accumulation of misfolded proteins, including beta-amyloid plaques, which are thought to contribute to the development and progression of SEs.

One of the key challenges in studying the role of POLRMT in SEs is its ability to cross the blood-brain barrier and its stability in the brain. Despite these challenges, research into the role of POLRMT in SEs has led to several promising findings.

One of the key findings in the study of POLRMT in SEs was its ability to be expressed in the brains of individuals with the disease and to interact with beta-amyloid plaques. This suggests that POLRMT may play a role in the development and progression of SEs by contributing to the accumulation of beta-amyloid plaques in the brain.

Another study found that POLRMT was overexpressed in the brains of individuals with SEs and that this increase in expression was associated with the level of beta-amyloid plaque formation. This suggests that increased levels of POLRMT may contribute to the development of SEs by promoting the formation of beta-amyloid plaques.

In addition to its potential role in the development of SEs, POLRMT has also been shown to be a potential drug target. The high level of expression of POLRMT in the brains of individuals with SEs makes it an attractive target for small molecule inhibitors, which could be used to treat the symptoms of SEs.

One of the first drugs that was developed to specifically target POLRMT was called Remdesivir. This drug is currently being used to treat SEs and has been shown to be effective in reducing the formation of beta-amyloid plaques in the brain.

While the role of POLRMT in SEs is still being fully understood, it is clear that it is involved in the development and progression of these disorders. Further research is needed to fully understand the role of POLRMT in SEs and to develop effective treatments.

In conclusion, POLRMT is a protein that has been shown to be involved in the development and progression of SEs. Its ability to cross the blood-brain barrier and interact with beta-amyloid plaques makes it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of POLRMT in SEs and to develop effective treatments.

Protein Name: RNA Polymerase Mitochondrial

Functions: DNA-dependent RNA polymerase catalyzes the transcription of mitochondrial DNA into RNA using the four ribonucleoside triphosphates as substrates (PubMed:21278163, PubMed:33602924). Component of the mitochondrial transcription initiation complex, composed at least of TFB2M, TFAM and POLRMT that is required for basal transcription of mitochondrial DNA (PubMed:29149603). In this complex, TFAM recruits POLRMT to a specific promoter whereas TFB2M induces structural changes in POLRMT to enable promoter opening and trapping of the DNA non-template strand (PubMed:29149603). Has DNA primase activity (PubMed:18685103, PubMed:33602924). Catalyzes the synthesis of short RNA primers that are necessary for the initiation of lagging-strand DNA synthesis from the origin of light-strand DNA replication (OriL) (PubMed:18685103, PubMed:33602924)

The "POLRMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLRMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets